Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Oster

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2026
Leaderless RiPPs expand the repertoire of fungal secondary metabolitesSung Chul Park, Livia D S Oster, Jacob Golan, et al.
Leukemia & Lymphoma|January 4, 2018
Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic modelHoward S Oster, Gal Carmi, Alex Kolomansky, et al.
British Journal of Haematology|August 29, 2025
Next-generation morphology, a novel multilayer morphometric digital analysis, reveals both the basic topology and new trends of myelodysplasia of peripheral blood specimensBen-Zion Katz, Yakir Moshe, Dan Bensity, et al.
Hematological Oncology|July 8, 2020
Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survivalErel Joffe, Uri Greenbaum, Gili Man-El, et al.
Scientific Reports|June 17, 2026
Toward clinically relevant automated corneal biomanufacturing with human-derived FBS alternativesAlexandre Taoum, Julia S Oster, Ole Thaden, et al.
British Journal of Haematology|June 17, 2025
Can we identify individuals at risk to develop multiple myeloma? A machine learning-based predictive modelMoshe Mittelman, Ariel Israel, Howard S Oster, et al.
European Journal of Haematology|June 30, 2018
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?Uri Greenbaum, Erel Joffe, Kalman Filanovsky, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Ophthalmology|August 15, 2003
Retinopathy in patients with diabetic ophthalmoplegiaLucas Trigler, R Michael Siatkowski, Angela S Oster, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2026
Leaderless RiPPs expand the repertoire of fungal secondary metabolitesSung Chul Park, Livia D S Oster, Jacob Golan, et al.
Leukemia & Lymphoma|January 4, 2018
Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic modelHoward S Oster, Gal Carmi, Alex Kolomansky, et al.
British Journal of Haematology|August 29, 2025
Next-generation morphology, a novel multilayer morphometric digital analysis, reveals both the basic topology and new trends of myelodysplasia of peripheral blood specimensBen-Zion Katz, Yakir Moshe, Dan Bensity, et al.
Hematological Oncology|July 8, 2020
Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survivalErel Joffe, Uri Greenbaum, Gili Man-El, et al.
Scientific Reports|June 17, 2026
Toward clinically relevant automated corneal biomanufacturing with human-derived FBS alternativesAlexandre Taoum, Julia S Oster, Ole Thaden, et al.
British Journal of Haematology|June 17, 2025
Can we identify individuals at risk to develop multiple myeloma? A machine learning-based predictive modelMoshe Mittelman, Ariel Israel, Howard S Oster, et al.
European Journal of Haematology|June 30, 2018
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?Uri Greenbaum, Erel Joffe, Kalman Filanovsky, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Ophthalmology|August 15, 2003
Retinopathy in patients with diabetic ophthalmoplegiaLucas Trigler, R Michael Siatkowski, Angela S Oster, et al.
Pageof 8